The US Food and Drug Administration announced on 20 October 2026 its final approval of Zydus Lifesciences' Abbreviated New Drug Application (ANDA) for an Estradiol and Levonorgestrel Transdermal System (0.045 mg/0.015 mg per day) — the first generic of Bayer's Climara Pro.
The once-weekly patch treats moderate to severe menopausal hot flushes and night sweats and prevents postmenopausal osteoporosis in women with an intact uterus.
The ANDA carried a Competitive Generic Therapy (CGT) designation, making it eligible for 180 days of exclusivity from first commercial marketing.
It will be made at Zydus's Moraiya plant near Ahmedabad; US annual sales of the product are about USD 45.7 million (IQVIA, August 2026).
A US FDA designation for a generic of a drug facing inadequate generic competition. The FDA can speed review, and the first approved CGT applicant may get 180 days of exclusivity — which it forfeits if it does not start selling within 75 days of approval.
Simple Analogy: A head start for the first runner into an empty race.
The exclusivity attached to the approval is subject to its provisions
Created the ANDA route, under which a generic proves bioequivalence instead of repeating clinical trials
Added Section 506H to the FD&C Act, creating the Competitive Generic Therapy pathway
Approves medicines for the US market, including generics through ANDAs
Indian drug-maker (formerly Cadila Healthcare); among the larger Indian holders of US generic approvals
General Awareness > Business — pharma approvals
Abbreviated New Drug Application — the US route to approve a generic by showing it matches and is bioequivalent to a reference drug.
A skin patch that releases a drug through the skin into the bloodstream.